An evidence-based framework to determine funding requirements for NCCPs
The report finds that NCCPs rarely specify the funds that need to be committed or the spending that occurs in practice. When evidence of funding impact is...
Oncology consulting with cutting-edge strategies and comprehensive expertise
The treatment, policies, and study of oncology continue to undergo rapid changes and evolution, with each year bringing new opportunities and challenges for existing and new treatments. CRA positions itself on the cutting edge of the field, staying abreast of the latest issues and developments and allowing us to provide actionable, future-focused strategies for our clients.
CRA’s knowledge base stems from hundreds of engagements on solid and hematological tumors, working with clients on small molecules, monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), cell therapies, oncology vaccines, and the increasing range of combination approaches to treating cancer.
Why CRA for your strategic partner in oncology?
Engagements
- 01Developing market-access focused segmentation and typing tool to aid uptake of bispecific oncology productsA leading pharmaceutical company sought support from CRA’s Life Sciences consultants in understanding how to best segment, target, and activate key accessView engagement
- 02Understanding the PMA potential of future innovations in oncologyA leading pharmaceutical company sought support from CRA Life Sciences experts in the clinical development of several new monotherapy and combination productsView engagement
- 03Demand study on impact of new treatments in small cell lung cancer (SCLC)CRA’s Life Sciences Practice was retained by a medium-sized pharmaceutical client to understand how the introduction of a small new cell lung cancer (SCLC)View engagement
Contact an Oncology expert.
See all Oncology expertsRecent events
US Oncology in 2024 and Beyond: A Payer Perspective Webinar
This CRA-moderated 30-minute, intimate roundtable discussion focuses on several of the key ongoing and emerging topics in oncology and what this may mean for...
Oncology in 2024 and Beyond: A Payer Perspective Webinar
This CRA-moderated 30-minute, intimate roundtable discussion focuses on several of the key ongoing and emerging topics in oncology and what this may mean for...